At the news
? BEARISHIMPACT 7/10 EFFECT filed Mar 31, 2026 at 00:15 ET
InMed Pharmaceuticals' S-3 shelf registration has become effective, allowing the company to raise up to $50 million through future offerings of common shares, preferred shares, warrants, or other securities. Given the company's $2 million market cap and existing going concern doubts, this creates a significant dilution overhang.
- S-3 shelf registration became effective on March 30, 2026
- Company may raise up to $50 million in aggregate value over time
- Offering can include common stock, preferred stock, warrants, subscription rights, or units
- Market cap is only $2 million, implying potential for extreme dilution
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access